Staffan Jahnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Staffan Jahnson has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Abolfazl Hosseini Aliabad
B 2 Department of Urology, Karolinska University Hospital , Stockholm, Sweden
1 shared publication- Börje Ljungberg
Department of Diagnostics and Intervention, Urology and Andrology, Umeå University, Umeå, Sweden.
1 shared publication Fredrik Liedberg
D 4 Department of Urology, Skåne University Hospital , Malmö, Sweden
1 shared publicationGeorg Jancke
A 1 Department of Urology, IBK, Linköping University , Linköping, Sweden
1 shared publicationJohan Rosell
G 7 Department of Urology, Regional Cancer Center South East , Linköping, Sweden
1 shared publication- Per-Uno Malmström
Department of Surgical Sciences Uppsala University Uppsala Sweden
1 shared publication
Latest Publications
- 18 September 2015
- Published by Taylor & Francis in Scandinavian Journal of Urology
- Vol. 50 (1) , 14-20
Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment
Objective. The aim of this study was to use the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) to investigate changes in patient and tumour characteristics, management and survival in bladder cancer cases over a period of 15 years. Materials and methods. All patients with newly detected bladder cancer reported to the SNRUBC during 1997–2011 were included in the study. The cohort was divided into three groups, each representing 5 years of the 15 year study period. Results. The study included 31,266 patients (74% men, 26% women) with a mean age of 72 years. Mean age was 71.7 years in the first subperiod (1997–2001) and 72.5 years in the last subperiod (2007–2011). Clinical T categorization changed from the first to the last subperiod: Ta from 45% to 48%, T1 from 21.6% to 22.4%, and T2–T4 from 27% to 25%. Also from the first to the last subperiod, intravesical treatment after transurethral resection for T1G2 and T1G3 tumours increased from 15% to 40% and from 30% to 50%, respectively, and cystectomy for T2–T4 tumours increased from 30% to 40%. No differences between the analysed subperiods were found regarding relative survival in patients with T1 or T2–T4 tumours, or in the whole cohort. Conclusions. This investigation based on a national bladder cancer registry showed that the age of the patients at diagnosis increased, and the proportion of muscle-invasive tumours decreased. The treatment of all tumour stages became more aggressive but relative survival showed no statistically significant change over time.
- 18 September 2015
- Published by Taylor & Francis in Scandinavian Journal of Urology
- Vol. 50 (1) , 14-20
Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment
Objective. The aim of this study was to use the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) to investigate changes in patient and tumour characteristics, management and survival in bladder cancer cases over a period of 15 years. Materials and methods. All patients with newly detected bladder cancer reported to the SNRUBC during 1997–2011 were included in the study. The cohort was divided into three groups, each representing 5 years of the 15 year study period. Results. The study included 31,266 patients (74% men, 26% women) with a mean age of 72 years. Mean age was 71.7 years in the first subperiod (1997–2001) and 72.5 years in the last subperiod (2007–2011). Clinical T categorization changed from the first to the last subperiod: Ta from 45% to 48%, T1 from 21.6% to 22.4%, and T2–T4 from 27% to 25%. Also from the first to the last subperiod, intravesical treatment after transurethral resection for T1G2 and T1G3 tumours increased from 15% to 40% and from 30% to 50%, respectively, and cystectomy for T2–T4 tumours increased from 30% to 40%. No differences between the analysed subperiods were found regarding relative survival in patients with T1 or T2–T4 tumours, or in the whole cohort. Conclusions. This investigation based on a national bladder cancer registry showed that the age of the patients at diagnosis increased, and the proportion of muscle-invasive tumours decreased. The treatment of all tumour stages became more aggressive but relative survival showed no statistically significant change over time.